NGL Fine-Chem Limited (NGLFINE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, NGL Fine-Chem Limited (NGLFINE) has a cash flow conversion efficiency ratio of 0.056x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs167.72 Million ≈ $1.81 Million USD) by net assets (Rs3.00 Billion ≈ $32.47 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See NGLFINE equity financing ratio to measure how much of total assets are equity-financed.
NGL Fine-Chem Limited - Cash Flow Conversion Efficiency Trend (2009–2026)
This chart illustrates how NGL Fine-Chem Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check NGL Fine-Chem Limited (NGLFINE) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
NGL Fine-Chem Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of NGL Fine-Chem Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hexindo Adiperkasa Tbk
JK:HEXA
|
0.038x |
|
Crane Harbor Acquisition Corp. - Class A Ordinary Shares
NASDAQ:CHAC
|
-0.005x |
|
Evans Bancorp Inc
NYSE MKT:EVBN
|
-0.022x |
|
Paiho Shih Holdings Corp
TW:8404
|
0.039x |
|
Shin Yang Shipping Corporation Bhd
KLSE:5173
|
0.046x |
|
AURORA EIENDOM NK 75
F:IL7
|
N/A |
|
Journey Energy Inc
TO:JOY
|
0.041x |
|
GSI Technology Inc
NASDAQ:GSIT
|
-0.096x |
Annual Cash Flow Conversion Efficiency for NGL Fine-Chem Limited (2009–2026)
The table below shows the annual cash flow conversion efficiency of NGL Fine-Chem Limited from 2009 to 2026. For the full company profile with market capitalisation and key ratios, see NGL Fine-Chem Limited market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2026-03-31 | Rs3.29 Billion ≈ $35.60 Million |
Rs395.40 Million ≈ $4.28 Million |
0.120x | -5.31% |
| 2025-03-31 | Rs2.82 Billion ≈ $30.54 Million |
Rs358.22 Million ≈ $3.87 Million |
0.127x | +62.77% |
| 2024-03-31 | Rs2.63 Billion ≈ $28.40 Million |
Rs204.65 Million ≈ $2.21 Million |
0.078x | -50.85% |
| 2023-03-31 | Rs2.23 Billion ≈ $24.07 Million |
Rs352.86 Million ≈ $3.82 Million |
0.159x | +133.07% |
| 2022-03-31 | Rs2.03 Billion ≈ $21.98 Million |
Rs138.25 Million ≈ $1.50 Million |
0.068x | -61.59% |
| 2021-03-31 | Rs1.54 Billion ≈ $16.70 Million |
Rs273.54 Million ≈ $2.96 Million |
0.177x | -14.36% |
| 2020-03-31 | Rs989.61 Million ≈ $10.70 Million |
Rs204.64 Million ≈ $2.21 Million |
0.207x | +115.34% |
| 2019-03-31 | Rs921.23 Million ≈ $9.96 Million |
Rs88.47 Million ≈ $956.76K |
0.096x | -69.07% |
| 2018-03-31 | Rs720.42 Million ≈ $7.79 Million |
Rs223.65 Million ≈ $2.42 Million |
0.310x | +84.86% |
| 2017-03-31 | Rs585.12 Million ≈ $6.33 Million |
Rs98.26 Million ≈ $1.06 Million |
0.168x | -11.71% |
| 2016-03-31 | Rs442.15 Million ≈ $4.78 Million |
Rs84.10 Million ≈ $909.54K |
0.190x | -16.82% |
| 2015-03-31 | Rs328.16 Million ≈ $3.55 Million |
Rs75.04 Million ≈ $811.54K |
0.229x | +1990.49% |
| 2014-03-31 | Rs245.44 Million ≈ $2.65 Million |
Rs-2.97 Million ≈ $-32.11K |
-0.012x | -932.61% |
| 2013-03-31 | Rs200.15 Million ≈ $2.16 Million |
Rs-234.46K ≈ $-2.54K |
-0.001x | -101.43% |
| 2012-03-31 | Rs171.06 Million ≈ $1.85 Million |
Rs14.01 Million ≈ $151.47K |
0.082x | -66.15% |
| 2011-03-31 | Rs160.59 Million ≈ $1.74 Million |
Rs38.85 Million ≈ $420.12K |
0.242x | +140.92% |
| 2010-03-31 | Rs136.48 Million ≈ $1.48 Million |
Rs13.70 Million ≈ $148.20K |
0.100x | +413.97% |
| 2009-03-31 | Rs109.35 Million ≈ $1.18 Million |
Rs-3.50 Million ≈ $-37.82K |
-0.032x | -- |
About NGL Fine-Chem Limited
NGL Fine-Chem Limited manufactures and sells pharmaceuticals and intermediates for usage in veterinary and human health in India, Europe, the Asia Pacific, the United States, and internationally. The company offers animal health pharmaceutical ingredients, such as homidium chloride, nitroxynil, clorsulon, parvaquone, buparvaquone, isometamidium chloride hydrochloride, toldimfos sodium, butaphosph… Read more